Pluripotent stem cells in translation: a Food and Drug Administration-National Institutes of Health collaboration.

Recently, the U.S. Food and Drug Administration (FDA), the U.S. National Institutes of Health, and the stem cell research community have collaborated on a series of workshops that address moving pluripotent stem cell therapies into the clinic. The first two workshops in the series focused on preclinical science, and a third, future workshop will focus on clinical trials. This summary addresses major points from both of the recent preclinically focused meetings. When entering into a therapeutics developmental program based on pluripotent cells, investigators must make decisions at the very early stages that will have major ramifications during later phases of development. Presentations and discussions from both invited participants and FDA staff described the need to characterize and document the quality, variability, and suitability of the cells and commercial reagents used at every translational stage. This requires consideration of future regulatory requirements, ranging from donor eligibility of the original source material to the late-stage manufacturing protocols. Federal, industrial, and academic participants agreed that planning backward is the best way to anticipate what evidence will be needed to justify human testing of novel therapeutics and to eliminate wasted efforts.

Institutional profile: National Institute of Neurological Disorders and Stroke and National Institute of Mental Health.

The nervous system is consistently viewed as a target of high interest for stem cell-based therapeutics. In the USA, the National Institute of Neurological Disorders and Stroke (NINDS) and the National Institute of Mental Health (NIMH) are the two largest funders of neuroscience-related research within the NIH. Research spanning the spectrum of basic, translational and clinical science is conducted both on the NIH campus and through funding of extramural research organizations across the USA, and, to a lesser extent, worldwide. In this brief survey, we will present an overview of stem cell-related activities at the two neuroscience-focused NIH institutes.

In the newborn hippocampus, neurotrophin-dependent survival requires spontaneous activity and integrin signaling.

The nervous system develops through a program that first produces neurons in excess and then eliminates as many as half in a specific period of early postnatal life. Neurotrophins are widely thought to regulate neuronal survival, but this role has not been clearly defined in the CNS. Here we show that neurotrophins promote survival of young neurons by promoting spontaneous activity. Survival of hippocampal neurons in neonatal rat requires spontaneous activity that depends on the excitatory action of GABA. Neurotrophins facilitate recruitment of cultured neurons into active networks, and it is this activity, combined with integrin receptor signaling, that controls neuronal survival. In vivo, neurotrophins require integrin signaling to control neuron number. These data are the first to link the early excitatory action of GABA to the developmental death period and to assign an essential role for activity in neurotrophin-mediated survival that establishes appropriate networks.

Developmental neurotransmitters?

Previous studies support an early role for neurotransmitter signaling before synaptogenesis, but puzzlingly, a neurological phenotype is absent in embryonic mice that lack vesicular release. Demarque et al. (in this issue of Neuron) now report that early release of transmitter is unconventional in not requiring action potentials, Ca(2+) entry, or vesicle fusion, thus potentially reconciling the discrepancy.

Is there more to GABA than synaptic inhibition?

In the mature brain, GABA (gamma-aminobutyric acid) functions primarily as an inhibitory neurotransmitter. But it can also act as a trophic factor during nervous system development to influence events such as proliferation, migration, differentiation, synapse maturation and cell death. GABA mediates these processes by the activation of traditional ionotropic and metabotropic receptors, and probably by both synaptic and non-synaptic mechanisms. However, the functional properties of GABA receptor signalling in the immature brain are significantly different from, and in some ways opposite to, those found in the adult brain. The unique features of the early-appearing GABA signalling systems might help to explain how GABA acts as a developmental signal.